Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2015

Published: Jan-2015 | Format: PDF | Global Markets Direct | Number of pages: 42 | Code: MRS - 18503


Global Markets Directs, Proliferative Vitreoretinopathy (PVR) Pipeline Review, H1 2015, provides an overview of the Proliferative Vitreoretinopathy (PVR)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Proliferative Vitreoretinopathy (PVR), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Proliferative Vitreoretinopathy (PVR) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR)
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Proliferative Vitreoretinopathy (PVR) and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Proliferative Vitreoretinopathy (PVR) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Proliferative Vitreoretinopathy (PVR) pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Proliferative Vitreoretinopathy (PVR)
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2

List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Proliferative Vitreoretinopathy (PVR) Overview 6
Therapeutics Development 7
Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Overview 7
Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis 8
Proliferative Vitreoretinopathy (PVR) - Therapeutics under Development by Companies 9
Proliferative Vitreoretinopathy (PVR) - Therapeutics under Investigation by Universities/Institutes 10
Proliferative Vitreoretinopathy (PVR) - Pipeline Products Glance 11
Early Stage Products 11
Proliferative Vitreoretinopathy (PVR) - Products under Development by Companies 12
Proliferative Vitreoretinopathy (PVR) - Products under Investigation by Universities/Institutes 13
Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development 14
Promedior, Inc. 14
RestorGenex Corporation 15
RXi Pharmaceuticals Corporation 16
Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Drug to Inhibit TAK1 for Proliferative Viteroretinopathy - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
LD-224 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Oligonucleotide 2 for Age Related Macular Degeneration and Proliferative Vitreoretinopathy - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Oligonucleotide for Age Related Macular Degeneration and Proliferative Vitreoretinopathy - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
P-529 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
PRM-167 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
RNAi Oligonucleotide to Inhibit CTGF for PVR - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Proliferative Vitreoretinopathy (PVR) - Recent Pipeline Updates 35
Proliferative Vitreoretinopathy (PVR) - Dormant Projects 37
Proliferative Vitreoretinopathy (PVR) - Product Development Milestones 38
Featured News & Press Releases 38
May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform 38
May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering Technology Platform 38
May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 39
May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 40

Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables

Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H1 2015 7
Number of Products under Development for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Products under Investigation by Universities/Institutes, H1 2015 13
Proliferative Vitreoretinopathy (PVR) - Pipeline by Promedior, Inc., H1 2015 14
Proliferative Vitreoretinopathy (PVR) - Pipeline by RestorGenex Corporation, H1 2015 15
Proliferative Vitreoretinopathy (PVR) - Pipeline by RXi Pharmaceuticals Corporation, H1 2015 16
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 25
Proliferative Vitreoretinopathy (PVR) Therapeutics - Recent Pipeline Updates, H1 2015 35
Proliferative Vitreoretinopathy (PVR) - Dormant Projects, H1 2015 37

List of Figures
 

Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H1 2015 7
Number of Products under Development for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 11
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Top 10 Targets, H1 2015 18
Number of Products by Stage and Top 10 Targets, H1 2015 19
Number of Products by Top 10 Mechanism of Actions, H1 2015 20
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Top 10 Routes of Administration, H1 2015 22
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23
Number of Products by Top 10 Molecule Types, H1 2015 24
Number of Products by Stage and Top 10 Molecule Types, H1 2015 25

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing